Autopsy report · NCT04492254

Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients

“Average event rate (end point) was much lower than expected. A larger sample size would have been required to maintain same statistical power, which was not achievable in a feasible time scale. No safety concerns were identified with bleeding.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 1 month before it stopped.
• 219 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Thrombosis Research Institute

Sponsor type

University, hospital or other

Conditions

COVID-19

Interventions

Enoxaparin

Participants

219

Sites

3

Countries

Australia, Belgium, South Africa

Trials that died the same way

• Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma
  “there was an unacceptably high adverse event rate in the treatment group.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.